Clinical value for contrast-enhanced transrectal ultrasound in diagnosis of prostate cancer.
10.11817/j.issn.1672-7347.2018.08.010
- Author:
Min ZHANG
1
;
Minghui LIU
2
Author Information
1. Department of Ultrasound, Central Hospital of Changsha, Changsha 410008, China.
2. Department of Ultrasound, Second Xiangya Hospital, Central South University, Changsha 410011, China.
- Publication Type:Journal Article
- MeSH:
Contrast Media;
Endoscopic Ultrasound-Guided Fine Needle Aspiration;
methods;
Humans;
Male;
Prostate;
diagnostic imaging;
pathology;
Prostatic Neoplasms;
diagnostic imaging;
pathology;
Radiography, Interventional;
Sensitivity and Specificity;
Ultrasonography;
methods
- From:
Journal of Central South University(Medical Sciences)
2018;43(8):882-885
- CountryChina
- Language:Chinese
-
Abstract:
To explore the value for contrast-enhanced transrectal ultrasound (CETRUS) in the diagnosis of prostate cancer.
Methods: Prostate biopsy from 207 cases of suspected prostate cancer were collected between January 2013 and March 2015. These patients were performed ultrasound-guided prostate biopsy in Central Hospital of Changsha. They were randomly divided into a radiography group (n=104) and a non-radiography group (n=103) according to the order of treatment. Transrectal ultrasonography (TRUS) was the first choice in the 2 groups, and CETRUS was conducted in the radiography group. Then, the transrectal biopsy was carried out in the 2 groups. The diagnostic value of CETRUS in prostate cancer was evaluated by pathological examination, a gold standard.
Results: The sensitivity, specificity, and coincidence rates of TRUS in diagnosing prostate cancer were 65%, 60.4%, and 62.8%, respectively, while those rates of CETRUS in diagnosing prostate cancer were 89%, 78%, and 84%, respectively, with significant difference between the above 2 groups (all P<0.05).
Conclusion: The sensitivities, specificities, and coincidence rates for CETRUS are superior to TRUS in diagnosing prostate cancer, which can provide a clinical basis for the diagnosis and differential diagnosis of prostate cancer.
